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“It is not the strongest of the species that survives, nor the most intelligent, but the one most 
responsive to change.” Charles Darwin 
Summary 
The US and Hungarian statistical records, before the dramatic medical advances, for the 
years 1900 and 1896, respectively, show 32% and 27% deaths attributable to infections, 
whereas only 5% and 2% due to cancer. These data can be interpreted to mean that (i) the 
immune system evolved for purging nascent selfish cells, which establish natural chimerism, 
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littering the soma and the germline by conspecific alien cells and (ii) defense against 
pathogens that represent xenogeneic aliens appeared later in evolution. 
‘Liberating’ T cells from the semantic trap of immunity and the shackles of the ‘two-signal’ 
model of T cell activation, we point out theoretical grounds that the immune response to 
cancer is conceptually different from the immune response to infection. We argue for a one-
signal model (with stochastic influences) as the explanation for T cell activation in 
preference to the widely accepted two-signal model for co-stimulation. Convincing evidence 
for our one-signal model emerged from the widespread adverse autoimmune events in 72% 
of advanced melanoma patients treated with the anti-CTLA-4 antibody (ipilimumab) that 
blocks an immune checkpoint. Harnessing the unleashed autoimmune power of T cells could 
be rewarding to defeat cancer. Assuming that immunization against isogeneic tumors also 
would be effective is a fallacy. (202 words) 
Keywords: cancer deaths; infectious disease deaths; one-signal T cell model; ipilimumab; 
harnessing autoimmune T cells; fallacy of tumor immunology. 
1. Introduction 
Alfred Tauber proposed that “…’immunity’ may be a semantic trap that has confined 
our understanding of the immune system to only a narrow segment of defensive, aggressive 
functions” (1). Macfarlane Burnet suggested first regarding the evolutionary origin of adaptive 
immunity related to processes other than defense against pathogenic microorganisms (2). 
Satisfactory answers have not been available to explain ‘why invertebrates including more 
than two million species in more than 20 phyla use only germline encoded innate immunity’, 
or ‘why vertebrates reject any allogeneic or xenogeneic transplanted tissue’. Rinkevich, then 
challenged the tacit assumptions and dogma that evolution of the immune system is 
pathogenically directed (3). He proposed that immunity developed as a surveillance 
operation to purge nascent selfish cells. Such cells could be isogeneic tumors from the host 
or transmissible allogeneic cells from kin organisms establishing natural chimerism that 
littered the soma and the germline by conspecific alien cells. According to Rinkevich the 
primary role of the vertebrate immune defense is to combat these parasitic events and 
preserve the individual homogeneity. Somatic compatibility systems that deter genotypes 
from being contaminated by maladapted alien genotypes might be the origin of immunity (4). 
Defense against pathogens, which are xenogeneic aliens appeared later in evolution. 
Some current examples of parasitic allogeneic cells are instructive. Canine 
transmissible venereal tumor (CTVT) is a transmissible cancer allograft that rapidly spreads 
naturally in dogs worldwide (5). CTVT may have first arisen within a genetically isolated 
population of early dogs whose limited genetic diversity facilitated the escape of cancer from 
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the immune surveillance system of the host. The Tasmanian devil facial tumor disease 
(DFTD) is another highly aggressive cancer allograft presenting a serious extinction risk for 
the Tasmanian devil population (6). DFTD arose in an island population with low genetic 
diversity. It seems that populations with limited genetic diversity may be particularly 
susceptible to the emergence and spread of transmissible cancers. This way, transmissible 
allogeneic tumors might have contributed to the evolutionary force shaping the class I 
immune surveillance system (7). 
Based on the complementarity theorem of Dillon and Root-Bernstein (8) (9), we 
proposed that individual integrity can be preserved from parasitism with a limited repertoire. 
This is achieved by a homeostatic coupled system via internal dialogue between the 
positively selected, low affinity complementary T cells and host cells (10) (11). The role of 
regulatory T Cells (Foxp3+ Tregs) seems to be the closest analogy to the role of homeostatic 
T cells in our model, which is described in more details in (11). 
The thrust of this paper is a fresh approach to reconsider the evolutionary role of 
viruses with respect to cancer over millions of years for adaptation and survival. The viruses 
are not just hostile invaders, but the molecular biologic tools of “Nature’s genetic engineering 
laboratory” that have been influencing and regulating key aspects of our biology (12). 
Following Tauber, we liberate T cells from the semantic trap of immunity and suggest 
that the primary function of T cells is to prevent dedifferentiation that is,   “…in a world in 
which necessity is represented by an inevitable disappearance of differentiation.” 2 This way, 
T cells put strict limits on variations of host cells and prevent a natural tendency of people to 
develop tumors. 
Unexpectedly, the first robust vindication for this proposal emerged from the 
widespread autoimmune adverse events in advanced melanoma patients receiving the 
checkpoint blocking anti-CTLA-4 antibody (ipilimumab) (13) as described below. 
2. Ipilimumab clinical trials – Our alternative interpretation of severe, widespread 
autoimmune-related adverse events 
The developers of the inhibitory anti-CTLA-4 antibody, ipilimumab, started with the premise 
that in an individual with no pathology other than cancer, most CTLA-4 expressing T-cells are 
either effector cells engaged in an anti-tumor response or regulatory T-cells actively 
opposing that response (14). Therefore, a CTLA-4 blockade would then selectively target T 
cells involved in the anti-tumor immune response. Although ipilimumab improved survival in a 
minority of metastatic melanoma patients, the vast majority suffered autoimmune-related 
adverse events (irAEs). A recent meta-analysis of ipilimumab mediated irAEs in 1265 
patients from 22 clinical trials (15) included in the pooled analysis found a respective 
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incidence of 72 % (95 % CI, 65–79; I2, 81.94) for all-grade irAEs and 24 % (95 % CI, 18–30; 
I2, 79.97) for high-grade irAEs leading to hospitalization or intravenous treatment. The 
incidence of all-grade irAEs varied according to the dosage of the drug, from 61 % (95 % CI, 
56–66; I2, 0) in patients receiving ipilimumab at 3 mg/kg to 79 % (95 % CI, 69–89; I2, 85) in 
patients treated with ipilimumab 10 mg/kg. These results highlight the high risk of irAEs with 
anti-CTLA-4 drugs in patients with metastatic cancers. These are quite similar data to those 
of a retrospective review of safety data including 1498 patients treated with ipilimumab at 
various doses in 14 completed phase I–III trials, reporting inflammation drug-related adverse 
events in 64 %, with 18 % being of severe grades. 3 Life-threatening side effects, 
pathognomonic of acute graft-versus-host-disease (GVHD) and drug-related deaths (0.86%) 
have been reported in most trials (15) (16) (17). Notwithstanding, for some obscure reason, 
the CTLA-4 blockade is persistently thought to be tumor specific when clinical remission 
(partial or complete), or at least cancer stabilization, was noted for 60 % of patients who 
experienced an irAE. Objective tumor response rates were around 30 % in patients who 
developed autoimmune events, while 0–10 % of the other patients responded to treatment. 
In a study by Downey et al. (18), all complete responders experienced high-grade irAEs. 
These observations corroborate the idea of coupling autoimmunity and tumor immunity (15). 
We are inclined to suggest a cautious view that the widespread and dose-dependent 
irAEs of ipilimumab can be better explained by our one-signal T cell activation theory (11) 
(19) (20) (21) (22) than by the conventional two-signal T cell activation models. Our model 
suggests that all T cells are temporarily activated, expressing CTLA-4 that can then be 
targeted by anti-CTLA-4 antibodies. This is consistent with the immunological homunculus 
concept of Irun Cohen, who suggested that the immune system continuously responds to self 
(23) (24) (25) (26). Evolution may give an answer as to why such constant self peptide 
control is necessary. 
3. Viruses playing a pivotal role in evolution may increase the risk of DNA damage 
and cancer 
Viral genes outnumber cellular ones in the biosphere. The delivery of genes from virus to cell 
being invaded is far more overwhelming when compared with the reverse event, i.e. transfer 
of genes from host cells to viruses. Thus, viruses, apart from altering the cell surface 
molecular complex, the arena of specific interactions (27) (28) (29), have the unique ability to 
alter hundreds of genes with minimal genomic burden. Microarray analysis of transduced 
CD34+ cells with the GFP lentiviral vector revealed that a total of 513 genes were altered in 
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terms of expression. Out of these, 183 (35.2%) were up-regulated more than twofold while 
330 genes (64.4%) were down-regulated (30). 
It had been proposed (12) that ancient viruses in evolution have spontaneously acted 
as essential editors of the host genome. This way, viruses may be thought of as the 
molecular biologic tools of “Nature’s genetic engineering laboratory” able to manipulate key 
aspects of our biology. Such natural genetic engineering in evolution will have contributed to 
the emergence of evolutionary innovations. A recent analysis confirmed that horizontal gene 
transfer is a hallmark of animal genome, although awareness of this virus-host ecology was 
not a part of the original Darwinian Theory (31) (32) (33) (34) (35) (36) (37). 
Natural genetic engineering mediated by viruses is a double-edged sword. Whereas 
viral gene transfer speeded up the evolution of the species, viral remnants, e.g. jumping 
genes, represented a real danger to the individual by increasing the risk of DNA damage, 
cancer, and other maladies. Genomes with various interactions occurring are likely to be 
hotbeds of evolutionary conflict.  4 
Consistent with the hypothesis that defense against pathogens appeared later in 
evolution, epidemiological observations support the view that the immune system is far from 
being infallible against pathogens. 
4. Before modern medicine, people succumbed to infections at much earlier age 
not living long enough to get cancer 
The demographic transition from high to low mortality (38) occurred following the discovery of 
antibiotics and successful immunization programs. Before these medical achievements the 
likelihood of an individual dying prematurely from infectious diseases was as high as 40%. 5 
As Mukherjee emphasized, prior to the miracles of modern medicine, “people didn’t live long 
enough to get cancer. Men and women were long consumed by tuberculosis, dropsy, 
cholera, smallpox, leprosy, plague, or pneumonia (39).” 
In contrast to the 40% death rate by infections, only one-third of humans are struck by 
cancer, mainly with advancing age (40). Fortuitously, good supporting historical evidence is 
available in the Statistical Yearbook of Hungary from 1896 about all-causes and cause-
specific mortality. We created an interactive figure using the visualization tool Krona (41). 6 7 
The data show that deaths due to infections were 27%, whereas deaths due to cancer were 
only 2%. It must be noted that the mortality rate of 27% from infectious diseases is a 
conservative estimate, since pneumonia, bronchitis, meningitis and encephalitis were not 
included therein in the infectious disease category. It is noteworthy that a similar difference 
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between the mortality rate from infectious disease and other disease states was recorded in 
the USA. Cutler and Meara reported that at the beginning of the 20th century, death due to 
infections was 32%, whereas only 5% due to cancer. 8 In the low-income countries, where 
the miracles of modern medicine are still not readily available, this ratio (28% vs. 6%) had not 
changed much by 2012. 9 10 11 
5. Slow growing tumor cells induce tolerance 
Carcinogenesis is a long-lasting step-by-step progression of early-stage lesions of cancer 
into frankly malignant cells. In addition, it is noteworthy that it takes as long as 12 years for 
cancer cells to reach a population size of 109 cells contained within ~0.5 cm3, weighing ~0.5 
g (42). Consistent with this, the average age of women with pre-invasive lesions was about 
20 years lower than for those with invasive lesions. 12 The risk of cancer increases 
exponentially with age (43). The risk of breast cancer, for example, increases from 1 in 400 
at thirty years of age to 1 in 9 at seventy years of age. Age-incidence curves rise sharply 
above the age of 50 years and are informative about the dynamics of tumor progression, the 
straight line showing a fit with power 4.8 (44). 
The slow growth of tumor cells is consistent with Pardoll’s suggestion that specific 
immune surveillance systems operate at early stages of tumorigenesis, whereas established 
tumors induce immune tolerance (45). The latter phenomenon is explained by the 
discontinuity theory of immunity claiming that the speed of antigenic change determines T 
cell activation. That is, the elimination of target cells is induced by an antigenic discontinuity, 
following a sudden modification of molecular motifs with which T cells interact (46). 
The paradox of cancer appears not to be “why does it occur”, but rather “why does it 
occur so infrequently” (47). It perhaps bears repeating that in fact, most human malignant 
tumors are latent for many years and became ‘old’ by the time they are detectable clinically, 
when termed incipient cancer. Although two out of three humans never develop clinically 
detectable cancer (40), most individuals with no apparent pathology, but having died of 
trauma, at autopsies were discovered to have been harboring unsuspected microscopic 
primary cancers (48) (49). The risk of suffering any cancer before the age of 40 is ~2%, but 
by age 80 this risk increases to 50% (50). For this so called tumor dormancy, it was 
suggested that cancer may be thought of as a chronic disease, which is kept in check by the 
patients’ own immune system and physiological mechanisms (51). 
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6. The explosive replication speed of microbes can only be controlled with non-
cytopathic mechanisms 
Numbers of bacteria double in 20 min, whereas viruses produce more than 1,000 progeny in 
a few hours generating hundred-times more virus infected cells within a few days than 
cancer cells develop during twelve years (see below). The question arises as to how do 
specific cytotoxic T lymphocytes (CTL) cope with virus infected cells? 
In this connexion hepatitis B and C virus (HBV, HCV) infections are good examples. 
According to Guidotti and Chisari (52), in the unlikely event of all the 108 HBV-specific CTL in 
the entire body entering the liver at the same time and all the 1011 hepatocytes quite 
commonly infected, for every 1,000 infected hepatocytes, there would be only one specific 
CTL in the liver to cope with the infection. Obviously, 1:1000 ratio would be totally inadequate 
for cytotoxic mechanism alone. Nevertheless, the immune system of most infected patients 
clears the virus within a few weeks without serious liver disease. This fact indicates the 
contribution of non-cytopathic mechanisms. Similarly, this occurs in HCV infections as well 
(53). 
7. The law of independent T cell activation is consistent with recent clinical 
observations 
The consensus view still is that the immune system is a complex and powerful defense 
mechanism (54). In order to keep this power under control T cell antigen receptor (TCR) 
input must be complemented by CD28 co-stimulation to promote interleukin-2 (IL-2)–
dependent proliferation, as described by the classic “two-signal” model of T cell activation 
(55). This is taken to mean that each cell requires the conjoint signals within it for these two 
receptors triggering activation to a state suitable for cell division (56). 
In contrast, the law of independence of T cell activation described by Gett and Hodgkin 
(57) states that the internal mechanisms that control the rate of division, the likelihood of 
surviving and the likelihood of undergoing a differentiation operate independently within a 
cell. In fact, the strength of a T cell response can be predicted by adding together the 
underlying signal components from the TCR, co-stimulatory receptors, and cytokines. This 
law resolved the co-stimulation paradox and provided a quantitative paradigm for 
therapeutically manipulating immune response strength (58). Consequently, there is no need 
for an obligatory co-stimulus for the decisions between tolerance and activation. 
This law is confirmed by recent clinical observations, which demonstrated that one 
signal alone was sufficient to trigger uncontrolled T cell stimulation via the CD28 receptor or 
the CTLA-4 receptor (19). The cytokine storm induced by the “superagonist” anti-CD28 mab 
(TGN1412) in the Northwick Park, Harrow, clinical trial catastrophe demonstrated that T 
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cells, depending on the high ligand concentration (see in (59) especially fig. 2), can be 
activated via a single receptor. Similarly, anti-CTLA-4 antibodies (during ipilimumab therapy) 
were able to stimulate the T cell system indirectly by blocking the CD28 antagonist CTLA-4 
co-receptors. In these interactions T cell pathways responsible for immune down-regulation 
were interrupted resulting in a dose-dependent, unrestrained, pan-lymphocytic T cell 
activation. This then turned homeostasis into overt autoimmunity (60) (61), thereby provoking 
an autologous graft versus host-like disease (GVHD) with severe, life-threatening 
autoimmune side effects. 
8. The fallacy of the infectious disease vaccination model of cancer immune 
therapy 
One of the greatest triumphs of medicine was the discovery of immunization against 
infectious diseases. Successful vaccination programs have been developed against 27 
different diseases. Vaccination against smallpox, which killed 300 to 500 million people even 
in the 20th century, enabled the infection to be declared eradicated from the world in 1980. 13 
Following the success of vaccines against xenogeneic infectious diseases, the tacit 
assumption, historically, has been that host immunity should be protective against isogeneic 
cancer as well. Following the simple principle of logic, assuming that immunity should be 
successful to defeat cancer as well, we submit that this makes it a fallacy. It is useful to 
consider the following reasons: (i) most spontaneous tumors in humans have no neoantigen 
(they are part of self), (ii) each tumor is a unique entity – a unique invention of nature (62), 
(iii) consistent with this, nearly all neoantigens in ipilimumab treated melanoma patients were 
patient-specific and most likely represent “passenger” mutations that do not directly 
contribute to tumorigenesis (63), but may have enhanced ipilimumab induced GVHD and (iv) 
tumors grow very slowly compared to pathogens (even a fast growing tumor with a doubling 
time of 10 days, less than 10 tumor cells will be present in a month, whereas 1011 
hepatocytes are infected during the same time; see above). Due to these characteristics 
human tumors are either unable to activate a sufficient number of antigen presenting cells 
(APCs) or APCs are less efficient in responding to isogeneic variants to promote interleukin-2 
(IL-2)–dependent co-stimulation of T cell before tolerance will have generated (45). 
9. Tolerance breakdown is required for eradication of isogeneic tumors 
Conventional cancer immunotherapy trials conducted with the best available science resulted 
in anecdotal responses. It is generally acknowledged that immunotherapy of cancer has not 
quite fulfilled the great promise and hopes of conquering cancer losing credibility (64). 
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Studies initiated by James P. Allison led to the breakthrough to treat a variety of 
malignancies. This was achieved by a prolonged overstimulation via immune checkpoint 
blockade by antibodies that target negative regulators of T-cell activity such as the cytotoxic 
T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 
pathway (PD-1/PD-L1) (65). The checkpoint blockade extends the expiration of activated T-
cell at various stages of the immune response. 
CTLA-4 receptors of T cells are an indispensable braking mechanism on T cell 
activation to ensure tolerance to self-tissues. Should CTLA-4 not function due to a genetic 
deficiency or if it is blocked by various manipulations, CD28 functions unopposed and swings 
the balance in favor of immune stimulation resulting in breakdown of tolerance (19). Anti-
CTLA-4 antibody (ipilimumab) improved survival of metastatic melanoma patients by 
disabling the brakes of T cells. Thus, the price we pay for reversing immunosuppression in 
cancer by a prolonged immune checkpoint blockade is the generation of uncontrolled T-cell 
activation. 
Successful targeting CTLA-4 has created enthusiasm for clinical approaches targeting 
other immunologic checkpoints, namely PD-1/PD-L1. After years of skepticism on lung 
cancer immune therapy in patients with metastases, trials on anti-PD-1/PD-L1 antibodies 
(nivolumab and pembrolizumab, respectively) provided results never observed with 
previously known drug categories (66). 
10. Worldwide increasing incidence of asthma affecting over 300 million people an 
instructive example of immune imbalance provoked by one-signal 
The anti-CD28 (TGN1412) and anti-CTLA-4 (ipilimumab) antibody trials demonstrated that 
one-signal alone was sufficient to activate the immune system (see above). Another 
instructive example of immune imbalance provoked by one-signal is the rising prevalence of 
asthma. 
Especially, from after the 1960s in the so-called “Westernized” countries of the world, 
rapid urbanization and industrialization have increased air pollution. The exposures of 
populations have resulted in a sharp increase in the prevalence, morbidity, and mortality of 
asthma. Air pollutants (e.g. particulate matter) induce expression of co-stimulators, such as 
B7 (CD80/86) molecules, on the antigen presenting cells (APCs) providing prolonged “signal 
2” that then initiate T cell responses. Thus, environmental changes appear to be directly 
responsible for the pathophysiology of asthma, driving the development of the T helper type 
2 (Th2)-biased immune responses and the overproduction of cytokines. Under such 
conditions then the immune system gets dysregulated mistaking pollen for pathogen reacts 
when it really should not. The prevalence of asthma is rising also in low and middle income 
countries as they adopt a more Western-type lifestyle. In China, for example, where 1.9 
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billion tons of coal is burnt each year to meet the 70 to 75% of the energy needs, outdoor 
pollution is associated with more than 300,000 deaths and 20 million cases of respiratory 
illnesses annually. So far asthma has affected more than 300 million people worldwide and 
the incidence is rising (67) (68). 
The consequences of prolonged overstimulation of the B-7/CD28 axis by drugs or 
pollutants are persuasive enough to consider a critical re-examination of the conventional 
two-signal theory, invoking an obligatory co-stimulus for T cell activation as described below. 
THE ONE-SIGNAL MODEL – A PAINTING WITH BROAD BRUSH STROKES 
Numerous receptor-mediated signals are delivered to T cells, governing their survival, 
differentiation and proliferation. For the sake of simplicity, only two positive and one negative 
signals are depicted in Figure 1. 
 
Figure 1. Activation of T-cells: Numerous receptor-mediated signals are delivered to T cells, which 
direct their survival, activation, differentiation and proliferation. For the sake of simplicity, here only an 
APC and a T cell are depicted with two ligands on APC (MHC and B7 [CD80/CD86]) and three 
receptors on T cell (TCR; CD28; and CTLA-4). The TCR and the CD28 receptor mediated signals are 
stimulatory, whereas the CTLA-4 receptor mediated signal is inhibitory in our model. Further details 
see in the text. 
In our model stochastic processes govern all the events. Based on the law of 
independent T cell activation (57), the likelihood of survival, activation, undergoing a 
differentiation change and clonal division operate independently within a cell. In other words, 
Bakacs et al. Viruses as nature’s genetic engineering tools February 28th 2016 
11 
 
one signal should be sufficient to instigate these events. Signal strength (via one or several 
receptors) determines the outcome of T cell activation. Low affinity, short-lasting TCR ligation 
ensures T cell survival, increased ligation time and or affinity induces cytotoxicity, whereas 
the strongest signal (long ligation time and or high affinity) induce clonal division. This may 
require stimulation via more than one receptor (e.g. TCR and CD28) such that the TCR-
dependent effects are strengthened by co-stimulation amplifying the T cell number 
exponentially through minimal kinetic alterations. The activities of the model are described in 
greater detail hereunder the following headings: (1) T cell survival (2) tumor prevention; (3) 
defense against primary infections; (4) secondary immune response; (5) autoimmune 
disease and (6) iatrogenic tolerance breakdown. 
1. T cell survival 
As already stated, the homeostatic coupled system functions via an internal dialogue 
between positively selected low affinity complementary T cells and host cells (10) (11). 
Recognition of ubiquitous and constitutive self-antigens by complementary T cells not only 
reliably sustains natural tolerance preventing dedifferentiation, but also ensures attacking 
cells presenting non-self peptides (see below). 
2. Tumor prevention (surveillance) 
The success of multicellularity depends upon the evolution of mechanisms that are able to 
suppress the ability of virtually every cell in an organism with the information and the 
potential to propagate rapidly (50). Rinkevich suggested that the immune system has 
developed as a surveillance machinery for nascent selfish cells stemming from a kin 
organism or from transformed cells within the organism of origin (3). Protective mechanisms 
that evolved over millions of years are indeed capable to keep the incidence of cancer very 
low (~2%) during reproductive age (50). It should, however, be noted that despite 
appearances, the mechanism of primary protection against cancer is different from primary 
protection against infections (see below). 
We hypothesize that cancer protection is carried out via cognate (complementary) 
TCR-MHC interactions (see Fig. 1) such that T cells keep the number of somatic cells 
constant. Paraphrasing Georg Klein (40), it would appear that evolution may have exploited 
over expression of a relatively limited number of common resistance genes to nip in the bud 
the incipient cancerous foci. Such preventive protection is all the more important since 
cancer is a state in which the epigenome is allowed to have greater plasticity than it is 
supposed to have in normal somatic tissues. It was argued that this increased epigenetic 
plasticity allows for selection in response to the cellular environment for cellular growth 
advantage at the expense of the host (69). 
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Up-regulated genes in transformed cells increase the expression of self peptides, 
which in turn, increase their affinity for interaction with the TCRs. This way, short-lasting life-
sustaining physiological stimulation of T cells is extended into a longer-lasting one that 
induces cytotoxicity. This local destructive autoimmunity eliminates altered (pre-cancerous) 
host cells. This is encompassed in the real meaning that molecular complementarity between 
TCR and MHC molecules puts strict limits on variations. The proof-of-principle that amplified 
or overexpressed genes are capable of inducing robust antitumor efficacy in T cells without 
destruction of normal tissues was recently demonstrated (70). 
Notwithstanding, cancer is virtually inevitable in complex, long-lived, multicellular 
organisms. Extrapolating from the risk of affliction with any cancer, practically everybody will 
have developed cancer as human lifetime approaches one-hundred years (see figure 4 in 
(50)). This is due to the fact that somatic mutations inevitably accumulate with time and 
capable to overcome the suppressive mechanisms. 
3. Defense against primary infections 
The probability is greater that the presentation of foreign peptides decreases rather than 
increasing the affinity for interaction with the TCRs during primary infections (10). While 
specific TCR-MHC contacts are inhibited, CD80/86-CD28 engagements are not. Microbial 
products (e.g. endotoxin) increase the local concentration of the CD80 and CD86 ligands on 
APCs (e.g. dendritic cells) by stimulating toll like receptors (TLRs). CD28 receptors of 
bystander T helper cells (Th) will then be saturated with CD80/86 ligands. Consequently, Th 
cells in the anatomical region are activated via the CD28 receptor alone (59). This triggers a 
limited beneficial local cytokine storm unleashing polyclonal T cytotoxic (Tc) cell proliferation 
to attack infected cells. These events initiate predominately immunopathology and to a lesser 
extent, autoimmunity by inducing indiscriminately anti-self and anti-non-self killing. This may 
well be thought of as a physiological local transplantation reaction. 
4. Pathogen specific secondary immune response 
In the presence of ongoing robust non-associative CD80/86-CD28 interactions (co-
stimulation), there is always a possibility that rare T cell (and B cell) clones with higher affinity 
may well recognize foreign peptides (antigens) via MHC-Ag-peptide-TCR signal (or via 
BCR), particularly when a significant fraction of host cells is infected and viral load is high (for 
example in hepatitis, see in (53)). Such higher affinity specific interactions would then drive 
activation, proliferation of T cell clones, and eventually lysis of infected cells, as described by 
the conventional two-signal models. Having cleared the infection, specific T cells would 
expand into memory type T cell clone, while B cells would differentiate into antibody 
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producing plasma cells (71). Specific T and B cell activation, proliferation and lysis of infected 
cells, therefore, obey the rules of the conventional two-signal model. 
5. Accidental autoimmune disease 
During an infection, when infected host cells lose their complementary Tc cell contact, 
autoreactive Tc cells with high affinity for a self peptide-MHC complex may be generated 
randomly, albeit with a small probability. This is consistent with the observations that 
autoimmunity might be thought of as a by-product of the immune response to microbial 
infection (72). 
6. Ipilimumab therapy and unanticipated consequences of iatrogenic breakdown of 
tolerance 
Ipilimumab therapy that induces blockade of CTLA-4 disabling the brakes on T cells, 
artificially prolongs the survival signal of complementary (autoreactive) T cells and turns 
homeostasis into overt autoimmunity. This induces a dose-dependent, unrestrained, pan-
lymphocytic T cell activation, which lasts so long as the CTLA-4 receptor blockade is 
sustained. This unfortunately results in unintended severe widespread, often life-threatening 
autoimmune side effects, including autologous graft versus host disease (GVHD). Under 
such conditions a genuine monoclonal autoimmunity may also be triggered (19) (20) (21). 
Conclusions 
Immunotherapy trials conducted with the best available science so far have not quite fulfilled 
the great promise and hopes of conquering cancer. Most spontaneous tumors are a part of 
self, a unique invention of nature. Nearly all neoantigens represent “passenger” mutations 
that do not directly contribute to tumorigenesis. The autoimmune power of T cells unleashed 
by the blockade of immune checkpoints should be harnessed for curing cancer. Tacitly 
assuming that immunization, which was so dramatically successful overcoming xenogeneic 
infections, should also be successful against isogenic tumours to defeat cancer surely is a 
fallacy. 
While we pointed out the pitfalls and drawbacks of ipilimumab, we also recognized its 
potentials that had remained undiscussed. We suggested extending the use of ipilimumab to 
eradicate minimal residual disease (MRD) following induction of complete remission by high 
dose chemotherapy and autologous stem cell transplantation, or following reduced intensity 
conditioning in preparation for allogeneic stem cell transplantation (SCT) using donor 
lymphocyte infusion (DLI) if indicated (21). On the other hand, in patients with high tumor 
burden, the forces of the immune system liberated by the co-stimulatory anti-CTLA-4 
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antibody blockade could be tethered to the tumor cells without collateral damage to normal 
cells using pretargeting (20). 
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